[Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia]

C Rohrmeier; T S Kühnel

doi:10.1007/s00106-011-2458-x

[Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia]

HNO. 2012 Nov;60(11):1003-6. doi: 10.1007/s00106-011-2458-x.

[Article in German]

Authors

C Rohrmeier¹, T S Kühnel

Affiliation

¹ Klinik für Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland. christian.rohrmeier@klinik.uni-regensburg.de

PMID: 22706563
DOI: 10.1007/s00106-011-2458-x

Abstract

We report on the submucosal injection of bevacizumab (Avastin) at a dose of 0.3 to 3.75 mg per side in a patient with hereditary hemorrhagic telangiectasia. Application of such low doses has not been described in the literature yet. Our case report shows the positive effect of low-dose bevacizumab on therapy-refractory epistaxis. No complications were caused by the bevacizumab treatment.

Publication types

Case Reports
English Abstract

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage*
Bevacizumab
Epistaxis / diagnosis
Epistaxis / etiology*
Epistaxis / prevention & control*
Female
Humans
Middle Aged
Telangiectasia, Hereditary Hemorrhagic / complications*
Telangiectasia, Hereditary Hemorrhagic / diagnosis
Telangiectasia, Hereditary Hemorrhagic / drug therapy*
Treatment Outcome

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab